Last edition
News about "Quizartinib "
Innovent and Daiichi Sankyo Partner for Vanflyta Commercialisation in China
Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement to commercialise Vanflyta in China, expanding access for FLT3-ITD positive AML patients.
Quizartinib | 11/08/2026 | By News Bureau
Daiichi Sankyo's quizartinib plus chemotherapy improves OS in patients with AML
Quizartinib combined with standard induction and consolidation chemotherapy and then continued as a single agent demonstrated a 22.4 per cent reduction in the risk of death
Quizartinib | 13/06/2022 | By Sudeep Soparkar | 966
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy